[go: up one dir, main page]

DZ2521A1 - Pharmaceutical compositions comprising 5-Ä4-Ä2- (methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜ-thiazolidine-2,4-dione and insulin for a method of treatment. - Google Patents

Pharmaceutical compositions comprising 5-Ä4-Ä2- (methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜ-thiazolidine-2,4-dione and insulin for a method of treatment.

Info

Publication number
DZ2521A1
DZ2521A1 DZ980131A DZ980131A DZ2521A1 DZ 2521 A1 DZ2521 A1 DZ 2521A1 DZ 980131 A DZ980131 A DZ 980131A DZ 980131 A DZ980131 A DZ 980131A DZ 2521 A1 DZ2521 A1 DZ 2521A1
Authority
DZ
Algeria
Prior art keywords
ethoxyübenzylü
thiazolidine
dione
pyridyl
insulin
Prior art date
Application number
DZ980131A
Other languages
French (fr)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2521A1 publication Critical patent/DZ2521A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DZ980131A 1997-06-18 1998-06-17 Pharmaceutical compositions comprising 5-Ä4-Ä2- (methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜ-thiazolidine-2,4-dione and insulin for a method of treatment. DZ2521A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
DZ2521A1 true DZ2521A1 (en) 2003-02-08

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980131A DZ2521A1 (en) 1997-06-18 1998-06-17 Pharmaceutical compositions comprising 5-Ä4-Ä2- (methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜ-thiazolidine-2,4-dione and insulin for a method of treatment.

Country Status (30)

Country Link
EP (1) EP0999837A1 (en)
JP (1) JP2002504138A (en)
KR (1) KR20010013843A (en)
CN (1) CN1133431C (en)
AP (1) AP1287A (en)
AR (2) AR012997A1 (en)
AU (1) AU8216398A (en)
BG (1) BG104059A (en)
BR (1) BR9810444A (en)
CA (1) CA2294141A1 (en)
CO (1) CO4940454A1 (en)
DZ (1) DZ2521A1 (en)
EA (1) EA004800B1 (en)
GB (1) GB9712866D0 (en)
HU (1) HUP0003260A3 (en)
ID (1) ID23951A (en)
IL (1) IL133143A0 (en)
IN (1) IN189723B (en)
MA (1) MA26511A1 (en)
NO (1) NO996265D0 (en)
OA (1) OA11517A (en)
PE (1) PE104499A1 (en)
PL (1) PL343123A1 (en)
SK (1) SK179399A3 (en)
TR (1) TR199903095T2 (en)
TW (1) TW587937B (en)
UA (1) UA70299C2 (en)
UY (1) UY25050A1 (en)
WO (1) WO1998057636A1 (en)
ZA (1) ZA985237B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
MXPA01010820A (en) 1999-04-23 2002-06-04 Smithkline Beecham Plc Novel pharmaceutical.
DE60036367T2 (en) * 1999-06-21 2008-05-29 Eli Lilly And Co., Indianapolis SYNERGISTIC USE OF THIAZOLIDINEDIONES AND GLUCAGON-LIKE PEPTIDE-1 AND THEIR AGONISTS FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES
JP2003503356A (en) * 1999-06-25 2003-01-28 メドトロニック ミニメド インコーポレイテッド Multidrug diabetes treatment
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
ES2295692T3 (en) * 2002-11-08 2008-04-16 F. Hoffmann-La Roche Ag NEW DERIVATIVES OF 4-ALCOXIOXAZOL REPLACED AS PPAR AGONISTS.
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (en) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 Solid oral preparation containing rosiglitazone and cetirizine hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714652A3 (en) * 1993-09-15 2007-01-17 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
KR19990036290A (en) * 1995-08-10 1999-05-25 로즈 암스트롱 Reduction of Exogenous Insulin Dosage in Non-insulin-Dependent Diabetic Patients
ATE259227T1 (en) * 1995-09-18 2004-02-15 Ligand Pharm Inc TREATMENT OF NIDDM (NON-INSULIN DEPENDENT DIABETES MELLITUS) WITH RXR AGONISTS

Also Published As

Publication number Publication date
GB9712866D0 (en) 1997-08-20
PL343123A1 (en) 2001-07-30
AR015894A1 (en) 2001-05-30
ID23951A (en) 2000-06-08
CO4940454A1 (en) 2000-07-24
EA004800B1 (en) 2004-08-26
AP1287A (en) 2004-06-26
IN189723B (en) 2003-04-19
TW587937B (en) 2004-05-21
SK179399A3 (en) 2000-11-07
EA200000042A1 (en) 2000-08-28
AR012997A1 (en) 2000-11-22
CN1260715A (en) 2000-07-19
HUP0003260A3 (en) 2001-12-28
KR20010013843A (en) 2001-02-26
NO996265L (en) 1999-12-17
CA2294141A1 (en) 1998-12-23
HUP0003260A2 (en) 2001-05-28
EP0999837A1 (en) 2000-05-17
JP2002504138A (en) 2002-02-05
IL133143A0 (en) 2001-03-19
AP9901718A0 (en) 1999-12-31
OA11517A (en) 2004-02-04
TR199903095T2 (en) 2000-08-21
BR9810444A (en) 2000-09-05
BG104059A (en) 2000-10-31
AU8216398A (en) 1999-01-04
MA26511A1 (en) 2004-12-20
PE104499A1 (en) 2000-01-13
UY25050A1 (en) 2000-09-29
NO996265D0 (en) 1999-12-17
ZA985237B (en) 2000-02-17
WO1998057636A1 (en) 1998-12-23
CN1133431C (en) 2004-01-07
UA70299C2 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
DZ2521A1 (en) Pharmaceutical compositions comprising 5-Ä4-Ä2- (methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜ-thiazolidine-2,4-dione and insulin for a method of treatment.
DZ2420A1 (en) Novel formulations comprising amoxycillin and clavulanate and process for their preparation.
ATE257703T1 (en) 1,3-THIAZOLES AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA, ALLERGIES AND DIABETES
DZ2753A1 (en) Hydroxamides of (4-arylsulfonylamino) -tetrahydropyran-4-carboxylic acids, process for their preparation and compositions containing them
DZ2581A1 (en) Aryloxyarylsulfonylaminohydroxamic acid derivatives process for their preparation and pharmaceutical compositions containing them.
NL300057I1 (en) Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing them.
GEP20032995B (en) 1-Amino-Alkylcyclohexane NMDA Receptor Antagonists
MA26420A1 (en) MIXED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOPOROSIS, AND METHOD FOR THEIR PREPARATION.
DZ2221A1 (en) 5- (2- (4- (1,2-Benzisothiazole-3-yi) -1-piperazinyl) -ethyl) -6-chloro-1,3-dihydro-2h-indole-2-one trioxide process for its preparation and pharmaceutical compositions containing it.
FR2732223B1 (en) PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION
MA26508A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING VARICONAZOLE, AND PROCESS FOR THEIR PREPARATION.
DZ2300A1 (en) Substituted 6,5-heterobicyclic derivatives, process for their preparation and pharmaceutical compositions containing them.
DZ2299A1 (en) Substituted 6,6-heterobicyclic derivatives, process for their preparation and pharmaceutical compositions containing them.
MA26516A1 (en) TARTRATE OF A SUBSTITUTED DIPEPTIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
DZ2539A1 (en) Pharmaceutical compositions for the treatment of insulin resistance.
NO972451L (en) Heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and process for use thereof
DZ2600A1 (en) Pharmaceutical combinations of amlodipine and estatin and process for their preparation.
DZ2550A1 (en) Azetidinylpropylpiperidine derivatives process for their preparation and pharmaceutical compositions containing them.
MA26608A1 (en) PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEART FAILURE.
FR2716075B1 (en) A method for enhancing the effectiveness of an agricultural chemical, enhancer and enhancer composition used in this method and agricultural chemical composition comprising this enhancer.
MA26487A1 (en) PROTEASE INHIBITOR HETEROCYCLECETOHYDRAZIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK0810883T3 (en) Conjugate containing DTPA and albumin for individual dosing of drugs
DZ2510A1 (en) Composition comprising 5-Ä4-Ä2- (n-methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione and process for its preparation.
NO972449L (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one-1,1-dioxide derivatives and preparations and process for use thereof
DZ2522A1 (en) Composition comprising an insulin sensitizer and insulin secretagogue for a method of treatment.